Antimalarial drug discovery: Efficacy models for compound screening

Nature Reviews Drug Discovery

Volumn 3, Issue 6, 2004, Pages 509-520

  Fidock, David A ^a   Rosenthal, Philip J ^b   Croft, Simon L ^c   Brun, Reto ^d   Nwaka, Solomon ^e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; BENFLUMETOL; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; DAPSONE; FANSIDAR; FLUOROOROTIC ACID; FOLIC ACID ANTAGONIST; FOSMIDOMYCIN; GELDANAMYCIN; GOSSYPOL DERIVATIVE; MEFLOQUINE; PROGUANIL; PYRONARIDINE; RIFAMPICIN; SULFADOXINE; TAFENOQUINE; THIOLACTOMYCIN; TRICLOSAN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; CHOLINE UPTAKE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW;

EID: 3042550882     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1416     Document Type: Review

References (108)

1. Greenwood, B. & Mutabingwa, T. Malaria in 2002. Nature 415, 670-672 (2002).
2. White, N. J. The treatment of malaria. N. Engl. J. Med. 335, 800-806 (1996).
3. Pagola, S., Stephens, P. W., Bohle, D. S., Kosar, A. D. & Madsen, S. K. The structure of malaria pigment β-haematin. Nature 404, 307-310 (2000).
4. Ursos, L. M. & Roepe, P. D. Chloroquine resistance in the malarial parasite, Plasmodium falciparum. Med. Res. Rev 22, 465-491 (2002).
5. Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. J. Infect. Dis. 184, 770-776 (2001).
6. Trape, J. F. The public health impact of chloroquine resistance in Africa. Am. J. Trop. Med. Hyg. 64, 12-17 (2001).
7. Plowe, C. V. Monitoring antimalarial drug resistance: making the most of the tools at hand. J. Exp. Biol. 206, 3745-3752 (2003).
8. Olliaro, P. et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348, 1196-1201 (1996).
9. Winstanley, P. Modern chemotherapeutic options for malaria. Lancet Infect. Dis. 1, 242-250 (2001).
10. Lang, T. & Greenwood, B. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect. Dis. 3, 162-168 (2003).
11. Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415, 686-693 (2002).
12. Nwaka, S. & Ridley, R. G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Rev. Drug Discov. 2, 919-928 (2003).
13. Guerin, P. J. et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect. Dis. 2, 564-573 (2002).
14. Dorsey, G., Vlahos, J., Kamya, M. R., Staedke, S. G. & Rosenthal, P. J. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J. Infect. Dis. 188, 1231-1238 (2003).
15. Looareesuwan, S., Chulay, J. D., Canfield, C. J. & Hutchinson, D. B. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am. J. Trop. Med. Hyg. 60,533-541 (1999).
16. Staedke, S. G. et al. Amodiaquine, sulfadoxine/pyrimethamine, and combinaton therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358, 368-374 (2001).
17. Schellenberg, D. et al. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 67, 17-23 (2002).
18. Dorsey, G. et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal ramdomised trial. Lancet 360, 2031-2038 (2002).
19. White, N. J. & Pongtavornpinyo, W. The de novo selection of drug-resistant malaria parasites. Proc. R. Soc. Lond. B 270, 545-554 (2003).
20. Nosten, F. et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297-302 (2000).
21. White, N. J. et al. Averting a malaria disaster. Lancet 353, 1965-1967 (1999).
22. Adjuik, M. et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359, 1365-1372 (2002).
23. van Vugt, M. et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94, 545-548 (2000).
24. Rosenthal, P. J., Sijwali, P. S., Singh, A. & Shenai B. R. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des. 8, 1659-1672 (2002).
25. Chakrabarti, D. et al. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J. Biol. Chem. 277, 42066-42073 (2002).
26. Rotella, D. P. Osteoporosis: challenges and new opportunities for therapy. Curr. Opin. Drug Discov. Devel. 5, 477-486 (2002).
27. Gelb, M. H. & Hol, W. G. Parasitology. Drugs to combat tropical protozoan parasites. Science 297, 343-344 (2002).
28. Ralph, S. A., D'Ombrain, M. C. & McFadden, G. I. The apicoplast as an antimalarial drug target. Drug Resist. Update 4, 145-151 (2001).
29. Waller, R. F. et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 95, 12352-12357 (1998).
30. Jomaa, H. et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285, 1573-1576 (1999).
31. Missinou, M. A. et al. Fosmidomycin for malaria. Lancet 360, 1941-1942 (2002).
32. Surolia, N. & Surolia, A. Triclosan offers protection against blood stages of malaria by ihibiting enoyl-ACP reductase of Plasmodium falciparum. Nature Med. 7, 167-173 (2001).
33. Perozzo, R. et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl ACP reductase. J. Biol. Chem. 277, 13106-13114 (2002).
34. Waller, K. L., Lee, S. & Fidock, D. A. in Genomes and the Molecular Cell Biology of Malaria Parasites (eds Waters, A, P. & Janse, C. J.) 501-540 (Horizon, New York, 2004).
35. Biagini, G. A., O'Neill, P. M., Nzila, A., Ward, S. A. & Bray, P. G. Antimalarial chemotherapy: young guns or back to the future? Trends Parasitol. 19, 479-487 (2003).
36. Gardner, M. J. et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
37. Kissinger, J. C. et al. The Plasmodium genome database. Nature 419, 490-492 (2002).
38. Wu, Y., Kirkman, L. A. & Wellems, T. E. Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc. Natl. Acad. Sci. USA 93, 1130-1134 (1996).
39. Fidock, D. A. & Wellems, T. E. Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc. Natl. Acad. Sci. USA 94, 10931-10936 (1997).
40. van Dijk, M. R., Janse, C. J. & Waters, A. P. Expression of a Plasmodium gene introduced into subtelomeric regions of Plasmodium berghei chromosomes. Science 271, 662-665 (1996).
41. Crabb, B. S. et al. Targeted gene disruption shows that Knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. Cell 89, 287-296 (1997).
42. Sidhu, A. B. S., Verdier-Pinard, D. & Fidock, D. A. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210-213 (2002).
43. Waters, A. P., Thomas, A. W., van Dijk, M. R. & Janse, C. J. Transfection of malaria parasites. Methods 13, 134-147 (1997).
44. Peters, W. & Robinson, B. L. In Handbook of Animal Models of Infection (eds. Zak., O. & Sande, M.) 757-773 (Academic, London, 1999).
45. Rathod, P. K., Ganesan, K., Hayward, R. E., Bozdech, Z. & DeRisi, J. L. DNA microarrays for malaria. Trends Parasitol. 18, 39-45 (2002).
46. Bozdech, Z. et al. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 1, E5 (2003).
47. Le Roch, K. G. et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 301, 1503-1508 (2003).
48. Lasonder, E. et al. Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 419, 537-542 (2002).
49. Florens, L. et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419, 520-526 (2002).
50. Greenbaum, D. C. et al. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 298, 2002-2006 (2002).
51. Noedl, H., Wongsrichanalai, C. & Wernsdorfer, W. H. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 19, 175-181 (2003).
52. Makler, M. T. & Hinrichs, D. J. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am. J. Trop. Med. Hyg. 48, 205-210 (1993).
53. van der Heyde, H. C., Elloso, M. M., vande Waa, J., Schell, K. & Weidanz, W. P. Use of hydroethidine and flow cytometry to assess the effects of leukocytes on the malarial parasite Plasmodium falciparum. Clin. Diagn. Lab. Immunol. 2, 417-425 (1995).
54. ter Kuile, F., White, N. J., Holloway, P., Pasvol, G. & Krishna, S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp. Parasitol. 76, 85-95 (1993).
55. 50) of antimalarial drugs against Plasmodium falciparum parasites in a serum-free medium. Am. J. Trop. Med. Hyg. 51, 214-218 (1994).
56. Gluzman, I. Y., Schlesinger, P. H. & Krogstad, D. J. Inoculum effect with chloroquine and Plasmodium falciparum. Antimicrob. Agents Chemother. 31, 32-36 (1987).
57. Berenbaum, M. C. A method for testing for synergy with any number of agents. J. Infect. Dis. 137, 122-130 (1978).
58. Ohrt, C., Willingmyre, G. D., Lee, P., Knirsch, C. & Milhous, W. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 46, 2518-2524 (2002).
59. Canfield, C. J., Pudney, M. & Gutteridge, W. E. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80, 373-381 (1995).
60. White, N. J. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41, 301-308 (1999).
61. Ponnudurai, T., Meuwissen, J. H., Leeuwenberg, A. D., Verhave, J. P. & Lensen, A. H. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans. R. Soc. Trop. Med. Hyg. 76, 242-250 (1982).
62. Templeton, T. J., Kaslow, D. C. & Fidock, D. A. Developmental arrest of the human malaria parasite Plasmodium falciparum within the mosquito midgut via CTRP gene disruption. Mol. Microbiol. 36, 1-9 (2000).
63. Moreno, A., Badell, E., Van Rooijen, N. & Druilhe, P. Human malaria in immunocompromised mice: new in vivo model for chemotherapy studies. Antimicrob. Agents Chemother. 45, 1847-1853 (2001).
64. Childs, G. E. et al. Comparison of in vitro and in vivo antimalarial activities of 9-phenanthrenecarbinols. Ann. Trop. Med. Parasitol. 78, 13-20 (1984).
65. Peters, W. et al. The chemotherapy of rodent malaria. XXVII. Studies on mefloquine (WR 142,490). Ann. Trop. Med. Parasitol. 71, 407-418 (1977).
66. Peters, W., Robinson, B. L. & Ellis, D. S. The chemotherapy of rodent malaria. XLII. Halofantrine and halofantrine resistance. Ann. Trop. Med. Parasitol. 81, 639-646 (1987).
67. Vennerstrom, J. L. et al. Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecanes. J. Med. Chem. 43, 2753-2758 (2000).
68. Posner, G. H. et al. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J. Med. Chem. 46,1060-1065 (2003).
69. Peters, W. & Robinson, B. L. The chemotherapy of rodent malaria. LVI. Studies on the development of resistance to natural and synthetic endoperoxides. Ann. Trop. Med. Parasitol. 93, 325-329 (1999).
70. Sanni, L. A., Fonseca, L. F. & Langhorne, J. Mouse models for erythrocytic stage malaria. Methods Mol. Med. 72, 57-76 (2002).
71. Wengelnik, K. et al. A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science 295, 1311-1314 (2002).
72. Singh, A. et al. Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2 a papain-family cysteine protease of rodent malaria parasites. Biochem. J. 368, 273-281 (2002).
73. Gysin, J. in Malaria: Parasite Biology, Pathogenesis and Protection (ed. Sherman, I.) 419-441 (ASM, Washington DC, 1998).
74. Alanine, A., Nettekoven, M., Roberts, E. & Thomas, A. W. Lead generation - enhancing the success of drug discovery by investing in the hit to lead process. Comb. Chem. High Throughput Screen. 6, 51-66 (2003).
75. Bleicher, K. H., Bohm, H. J., Muller, K. & Alanine, A. I. Hit and lead generation: beyond high-throughput screening. Nature Rev. Drug Discov. 2, 369-378 (2003).
76. Di, L. & Kerns, E. H. Profiling drug-like properties in discovery research. Curr. Opin. Chem. Biol. 7, 402-408 (2003).
77. Kuo, M. R. et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. 278, 20851-20859 (2003).
78. Yuvaniyama, J. et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nature Struct. Biol. 10, 357-365 (2003).
79. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
80. Venkatesh, S. & Lipper, R. A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89, 145-154 (2000).
81. Molzon, J. The common technical document: the changing face of the New Drug Appication. Nature Rev. Drug Discov. 2, 71-74 (2003).
82. Nzila, A. M. et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J. Infect. Dis. 181, 2023-2028 (2000).
83. Mutabingwa, T. et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358, 1218-1223 (2001).
84. Jiang, L., Lee, P. C., White, J. & Rathod, P. K. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob. Agents Chemother. 44, 1047-1050 (2000).
85. Razakantoanina, V., Nguyen Kim, P. P. & Jaureguiberry, G. Antimalarial activity of new gossypol derivatives. Parasitol. Res. 86, 665-668 (2000).
86. Bracchi-Ricard, V. et al. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Bhophys. 396, 162-170 (2001).
87. Banumathy, G., Singh, V., Pavithra, S. R. & Tatu, U. Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J. Biol. Chem. 278, 18336-18345 (2003).
88. Davioud-Charvet, E. et al. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J. Med. Chem. 44, 4268-4276 (2001).
89. Woodard, C. L. et al. Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases. J. Med. Chem. 46, 3877-3882 (2003).
90. Eckstein-Ludwig, U. et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424, 957-961 (2003).
91. Gero, A. M. et al. New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr. Pharm. Des. 9, 867-877 (2003).
92. Joet, T., Eckstein-Ludwig, U., Morin, C. & Krishna, S. Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. Proc. Natl Acad. Sci. USA 100, 7476-7479 (2003).
93. De, D., Krogstad, F. M., Byers, L. D. & Krogstad, D. J. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J. Med. Chem. 41, 4918-4926 (1998).
94. Stocks, P. A. et al. Novel short chain chloroquine analoques retain activity against chloroquine resistant K1 Plasmodium falciparum. J. Med. Chem. 45, 4975-4983 (2002).
95. Francis, S. E. et al. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 13, 306-317 (1994).
96. Haque, T. S. et al. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. J. Med. Chem. 42, 1428-1440 (1999).
97. Rosenthal, P. J. in Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery (ed. Rosenthal, P. J.) 325-345 (Humana, Totawa, New Jersey, 2001).
98. Shenai, B. R. et al. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother. 47, 154-160 (2003).
99. Vennerstrom, J. L. et al. Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5- tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecanes. J. Med. Chem. 43, 2753-2758 (2000).
100. Borstnik, K., Paik, I. H. & Posner, G. H. Malaria: new chemotherapeutic peroxide drugs. Mini Rev. Med. Chem. 2, 573-583 (2002).
101. Vaidya, A. B. in Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery (ed. Rosenthal, P. J.) 203-218 (Humana, Totowa, New Jersey, 2001).
102. Clough, B. & Wilson, R. J. M. in Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery (ed. Rosenthal, P. J.) 265-286 (Humana, Totawa, New Jersey, 2001).
103. McLeod, R. et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int. J. Parasitol. 31, 109-113 (2001).
104. Ohkanda, J. et al. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg. Med. Chem. Lett. 11, 761-764 (2001).
105. Blackman, M. J. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Curr. Drug Targets 1, 59-83 (2000).
106. Gupta, S., Thapar, M. M., Mariga, S. T., Wernsdorfer, W. H. & Bjorkman, A. Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp. Parasitol. 100, 28-35 (2002).
107. Chawira, A. N., Warhurst, D. C., Robinson, B. L. & Peters, W. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. Trans. R. Soc. Trop. Med. Hyg. 81, 554-558 (1987).
108. Peters, W. & Robinson, B. L. The chemotherapy of rodent malaria. LV. Interactions between pyronaridine and artemisinin. Ann. Trop. Med. Parasitol. 91, 141-145 (1997).